21 results on '"Multi-system inflammatory syndrome in children"'
Search Results
2. Síndrome multisistémico inflamatorio pediátrico (MIS-C/PIMS): bases inmunológicas que sustentan el tratamiento.
- Author
-
Toledo-Salinas, Carla, Castaño-Jaramillo, Lina María, Gutiérrez-Hernández, Alonso, and Scheffler-Mendoza, Selma Cecilia
- Abstract
Pediatric inflammatory multisystemic syndrome temporarily associated with COVID-19 (MIS-C/PIMS) is a new post-infectious condition, secondary to SARS-CoV2 infection. It has been characterized by an inflammatory response with multisystem involvement, involving several mechanisms of immune damage such as an exaggerated increase in cytokines and epithelial damage. Immunomodulatory treatment is aimed at controlling the manifestations of hyperinflammation, to stabilize and prevent long-term sequelae. [ABSTRACT FROM AUTHOR]
- Published
- 2023
3. Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children.
- Author
-
Reiff, Daniel D. and Cron, Randy Q.
- Subjects
- *
MULTISYSTEM inflammatory syndrome in children , *SYNDROMES in children , *COVID-19 , *BIOMARKERS - Abstract
Background: Multisystem inflammatory syndrome in children (MIS-C) is a severe, postinfectious manifestation of coronavirus disease 2019 (COVID-19) in the pediatric population. The disease is manifested by hyperinflammation and can result in cardiac dysfunction, coronary changes, and end-organ damage. Adequate timely treatment can prevent poor outcomes in the short term, but long-term data is lacking. Methods: A large single center MIS-C cohort was followed longitudinally after treatment with intravenous immunoglobulin (IVIG) ± glucocorticoids to determine the natural history of the disease and to describe improvement in laboratory markers and cardiac outcomes. Patient were stratified by disease severity and compared. Results: 137 patients were identified with demographics similar to previously described cohorts. Regardless of disease severity, when adequately treated, initial lab abnormalities rapidly improved by the 6–8 month follow-up period, with some resolved in as little as 1–2 weeks. Similarly, cardiac abnormalities improved quickly after treatment; all abnormalities resolved in this cohort by 1–2 months post-hospitalization. Conclusions: Although MIS-C is a serious sequela of COVID-19, when identified quickly and treated aggressively, laboratory abnormalities, coronary dilatation, and systolic dysfunction rapidly improve with minimal long-term morbidity or mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Diagnosis and Treatment of Multisystem Inflammatory Syndrome Following COVID-19 in Children
- Author
-
Leila Shahbaznejad, Azin Hajialibeig, Mohammad Reza Navaeifar, Zahra Doorandish, and Mohammad Sadegh Rezai
- Subjects
covid-19 ,multi-system inflammatory syndrome in children ,steroids ,Medicine ,Medicine (General) ,R5-920 - Abstract
Multisystem Inflammatory Syndrome in Children (MIS-C) is recognized as a life threatening complication of Coronavirus disease (COVID-19) in children which can affect major systems such as cardiovascular, respiratory, blood and coagulation, renal, and nervous system. Mild cases of MIS-C can be followed up closely, but, severe illnesses that require hospitalization or pediatric intensive care are also common. Treatment of these patients includes supportive measures to improve the function of vital organs such as the heart and arteries, respiration, and kidneys. Antiviral therapy is recommended in patients with clear involvement of the respiratory system. Treatment with empirical antibiotics and drugs effective in suppressing or modulating the immune system such as steroids in various doses, intravenous immunoglobulins, biologic drugs, anticoagulants, and antiplatelets are recommended. In case of shock or decreased cardiac function, vasopressor drugs are suggested along with supportive measures to maintain tissue perfusions such as albumin and compressed red blood cells. Timely diagnosis and appropriate treatments improve the patient's condition and evaluation of long-term complications of this disease should be done.
- Published
- 2021
5. Spectrum of SARS-CoV-2-Related Clinical Syndromes in Children: A Year in the Life.
- Author
-
Khan, Mahjabeen, Dang, LeQuan, Singh, Harjinderpal, Dalrymple, Austin, Miller, Aaron, and Tanios, Aline
- Subjects
- *
LENGTH of stay in hospitals , *COVID-19 , *SARS-CoV-2 , *CHILDREN'S hospitals , *RETROSPECTIVE studies , *CARDIOVASCULAR diseases , *MEDICAL care , *COMPARATIVE studies , *RESPIRATORY distress syndrome , *LONGITUDINAL method , *DISEASE complications - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a wide pediatric clinical spectrum. Initial reports suggested that children had milder symptoms compared with adults; then diagnosis of multisystem inflammatory syndrome in children (MIS-C) emerged. We performed a retrospective cohort study of hospitalized patients at a children's hospital over 1 year. Our objectives were to study the demographic and clinical profile of pediatric SARS-CoV-2-associated diagnoses. Based on the clinical syndrome, patients were classified into coronavirus disease 2019 (COVID-19; non-MIS-C) and MIS-C cohorts. Among those who tested positive, 67% were symptomatic. MIS-C was diagnosed in 24 patients. Both diagnoses were more frequent in Caucasians. Both cohorts had different symptom profiles. Inflammatory markers were several-fold higher in MIS-C patients. These patients had critical care needs and longer hospital stays. More COVID-19 patients had respiratory complications, while MIS-C cohort saw cardiovascular involvement. Health care awareness of both syndromes is important for early recognition, diagnosis, and prompt treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children
- Author
-
Daniel D. Reiff and Randy Q. Cron
- Subjects
multi-system inflammatory syndrome in children ,COVID-19 ,SARS-CoV-2 ,Microbiology ,QR1-502 - Abstract
Background: Multisystem inflammatory syndrome in children (MIS-C) is a severe, postinfectious manifestation of coronavirus disease 2019 (COVID-19) in the pediatric population. The disease is manifested by hyperinflammation and can result in cardiac dysfunction, coronary changes, and end-organ damage. Adequate timely treatment can prevent poor outcomes in the short term, but long-term data is lacking. Methods: A large single center MIS-C cohort was followed longitudinally after treatment with intravenous immunoglobulin (IVIG) ± glucocorticoids to determine the natural history of the disease and to describe improvement in laboratory markers and cardiac outcomes. Patient were stratified by disease severity and compared. Results: 137 patients were identified with demographics similar to previously described cohorts. Regardless of disease severity, when adequately treated, initial lab abnormalities rapidly improved by the 6–8 month follow-up period, with some resolved in as little as 1–2 weeks. Similarly, cardiac abnormalities improved quickly after treatment; all abnormalities resolved in this cohort by 1–2 months post-hospitalization. Conclusions: Although MIS-C is a serious sequela of COVID-19, when identified quickly and treated aggressively, laboratory abnormalities, coronary dilatation, and systolic dysfunction rapidly improve with minimal long-term morbidity or mortality.
- Published
- 2022
- Full Text
- View/download PDF
7. تشخیصو درمان سندرم التهابی چند سیستمی در کودکان به دنبال کووید-19.
- Author
-
لیال شهباز نژاد, آذین حاجی علی بیگ, محمدرضا نوایی فر, زهرا دوراندیش, and محمدصادق رضایی
- Abstract
Multisystem Inflammatory Syndrome in Children (MIS-C) is recognized as a life threatening complication of Coronavirus disease (COVID-19) in children which can affect major systems such as cardiovascular, respiratory, blood and coagulation, renal, and nervous system. Mild cases of MIS-C can be followed up closely, but, severe illnesses that require hospitalization or pediatric intensive care are also common. Treatment of these patients includes supportive measures to improve the function of vital organs such as the heart and arteries, respiration, and kidneys. Antiviral therapy is recommended in patients with clear involvement of the respiratory system. Treatment with empirical antibiotics and drugs effective in suppressing or modulating the immune system such as steroids in various doses, intravenous immunoglobulins, biologic drugs, anticoagulants, and antiplatelets are recommended. In case of shock or decreased cardiac function, vasopressor drugs are suggested along with supportive measures to maintain tissue perfusions such as albumin and compressed red blood cells. Timely diagnosis and appropriate treatments improve the patient's condition and evaluation of long-term complications of this disease should be done. [ABSTRACT FROM AUTHOR]
- Published
- 2021
8. Reversible Cerebral Vasoconstriction Syndrome and Multisystem Inflammatory Syndrome in Children With COVID-19
- Author
-
Atefeh Sadeghizadeh, Zahra Pourmoghaddas, Alireza Zandifar, Seyedeh Zahra Tara, Hamid Rahimi, Rana Saleh, Saba Ramezani, Mohammadreza Ghazavi, Omid Yaghini, Neda Hosseini, Nahid Aslani, Mohammad Saadatnia, and Arastoo Vossough
- Subjects
Male ,Headache Disorders, Primary ,Multi-system inflammatory syndrome in children ,Short Communication ,reversible cerebral vasoconstriction syndrome ,COVID-19 ,Constriction, Pathologic ,Systemic Inflammatory Response Syndrome ,Cerebrovascular Disorders ,Developmental Neuroscience ,Neurology ,thunderclap headache ,Pediatrics, Perinatology and Child Health ,Humans ,Female ,Neurology (clinical) ,Child - Abstract
Background Multi-system inflammatory syndrome in children (MIS-C) involves multiple organs and shows increased inflammatory markers. Since the onset of the COVID-19 pandemic, several studies have reported the association between severe COVID-19 and MIS-C. Reversible cerebral vasoconstriction syndrome (RCVS) presents with thunderclap headaches and multifocal reversible vasoconstriction on imaging. RCVS is very rare in children. This paper reports two cases of pediatric COVID-19 with severe MIS-C and clinical and imaging features indicative of RCVS. Methods Clinical, laboratory and imaging data of the patients were reviewed. The diagnosis of RCVS was confirmed based on clinical symptomatology and brain magnetic resonance imaging findings. Results Two pediatric patients with clinical findings compatible with severe MIS-C and hemodynamic compromise presented to the hospital. During their hospitalization course, they developed thunderclap headaches and neurological deficits. Both were receiving vasoactive agents, intravenous immune globulin (IVIG), and immunosuppressants. Imaging studies showed marked multifocal cerebral vasoconstriction in both cases and infarcts in one. The course and management of the patients will be presented. After controlling inflammation and elimination of triggers, both patients were ultimately symptom-free upon discharge. Cerebral vasoconstriction had completely resolved on follow-up imaging. Conclusions Although a variety of symptoms including headaches may be seen in pediatric COVID-19 patients with MIS-C, RCVS should be considered as a differential diagnosis in cases of thunderclap headache accompanied by neurologic signs in these patients. Imaging findings and follow-up are also key in establishing the diagnosis.
- Published
- 2022
9. Report of a Child With Febrile Status Epilepticus and Post-COVID Multi-System Inflammatory Syndrome
- Author
-
Gayatra Mainali, Helen Cheung, Soriayah Zaghab-Mathews, Holly C Appleberry, and Alexis Begezda
- Subjects
Pediatrics ,medicine.medical_specialty ,febrile infection related epilepsy syndrome (FIRES) ,Coronavirus disease 2019 (COVID-19) ,CNS Involvement ,Case Report ,Status epilepticus ,RJ1-570 ,multi-system inflammatory syndrome in children ,Refractory ,abnormal brain MRI ,medicine ,Abnormal brain MRI ,RC346-429 ,Uncertain significance ,Genetic testing ,COVID ,medicine.diagnostic_test ,business.industry ,General Medicine ,Febrile infection related epilepsy syndrome ,Neurology. Diseases of the nervous system ,medicine.symptom ,business ,status epileptics - Abstract
Multi-system Inflammatory Syndrome in Children (MIS-C) is a post infectious inflammatory syndrome following COVID infection. Previous case series have demonstrated that CNS involvement is less common and presents heterogeneously. The following case describes an infant with an initial presentation of refractory febrile status epilepticus. Genetic testing later showed multiple variants of uncertain significance. The patient met clinical criteria for MIS-C and had a markedly abnormal brain MRI with bilateral diffuse restricted diffusion (anterior > posterior). Clinically, the patient improved with pulse steroids and IVIg. This case highlights the importance of maintaining MIS-C in the differential as a trigger of Febrile Infection Related Epilepsy Syndrome (FIRES) with multi-organ involvement presenting 2-4 weeks after infectious symptoms and COVID exposure.
- Published
- 2021
10. Short to midterm follow-up of multi-system inflammatory syndrome in children with special reference to cardiac involvement.
- Author
-
Aziz OA, Sadiq M, Qureshi AU, Hyder N, Kazmi U, Batool A, Naz S, Mushtaq A, Bari A, and Rashid J
- Subjects
- Male, Humans, Child, Infant, Child, Preschool, Adolescent, Female, Aftercare, Follow-Up Studies, Patient Discharge, COVID-19 complications, Mucocutaneous Lymph Node Syndrome complications, Pericardial Effusion, Coronavirus Infections
- Abstract
Objectives: We aim to describe the early and upto 16 months follow-up of post-coronavirus disease (COVID), multi-system inflammatory syndrome in children (MIS-C), with special reference to cardiac involvement., Study Design: This cohort non-interventional descriptive study included patients <18 years admitted between May, 2020 and April, 2021. Based on underlying similarities, children were classified as post-COVID MIS-C with overlapping Kawasaki Disease, MIS-C with no overlapping Kawasaki Disease, and MIS-C with shock. Post-discharge, patients were followed at 1, 3, 6, 12, and 16 months., Results: Forty-one patients predominantly males (73%), at median age of 7 years (range 0.2-16 years) fulfilled the World Health Organisation criteria for MIS-C. Cardiac involvement was seen in 15 (36.5%); impaired left ventricle (LV) function in 5 (12.2%), coronary artery involvement in 10 (24.4%), pericardial effusion in 6 (14.6%) patients, and no arrhythmias. There were two hospital deaths (4.9%), both in MIS-C shock subgroup (2/10, 20%). At 1 month, there was persistent LV dysfunction in 2/5, coronary artery abnormalities in 7/10, and pericardial effusion resolved completely in all patients. By 6 months, LV function returned to normal in all but coronary abnormalities persisted in two patients. At last follow-up (median 9.8 months, interquartile range 2-16 months), in 36/38 (94.7%) patients, coronary artery dilatation was persistent in 2 (20%) patients., Conclusions: Children with MIS-C have a good early outcome, though MIS-C with shock can be life-threatening subgroup in a resource-constrained country setting. On midterm follow-up, there is normalisation of LV function in all and recovery of coronary abnormalities in 80% of patients.
- Published
- 2023
- Full Text
- View/download PDF
11. Elevated cardiac biomarkers and outcomes in children and adolescents with acute COVID-19.
- Author
-
Fremed MA, Healy EW, Choi NH, Cheung EW, Choudhury TA, Jiang P, Liberman L, Zucker J, Lytrivi ID, and Starc TJ
- Subjects
- Humans, Child, Adolescent, Retrospective Studies, SARS-CoV-2, Cohort Studies, Biomarkers, Natriuretic Peptide, Brain, COVID-19 epidemiology
- Abstract
Cardiac involvement associated with multi-system inflammatory syndrome in children has been extensively reported, but the prevalence of cardiac involvement in children with SARS-CoV-2 infection in the absence of inflammatory syndrome has not been well described. In this retrospective, single centre, cohort study, we describe the cardiac involvement found in this population and report on outcomes of patients with and without elevated cardiac biomarkers. Those with multi-system inflammatory syndrome in children, cardiomyopathy, or complex CHD were excluded. Inclusion criteriaz were met by 80 patients during the initial peak of the pandemic at our institution. High-sensitivity troponin T and/or N-terminal pro-brain type natriuretic peptide were measured in 27/80 (34%) patients and abnormalities were present in 5/27 (19%), all of whom had underlying comorbidities. Advanced respiratory support was required in all patients with elevated cardiac biomarkers. Electrocardiographic abnormalities were identified in 14/38 (37%) studies. Echocardiograms were performed on 7/80 patients, and none demonstrated left ventricular dysfunction. Larger studies to determine the true extent of cardiac involvement in children with COVID-19 would be useful to guide recommendations for standard workup and management.
- Published
- 2023
- Full Text
- View/download PDF
12. A case of MIS-C presenting with fever and rash.
- Author
-
Ho S, McShane M, and Dean A
- Published
- 2023
- Full Text
- View/download PDF
13. COVID-19 Risks: MIS-C and Under-Vaccination.
- Author
-
Mowery, Bernice D.
- Subjects
- *
COVID-19 vaccines , *SYSTEMIC inflammatory response syndrome , *COVID-19 pandemic - Abstract
The article discusses the etiology and recommended treatments for multisystem inflammatory syndrome in children (MIS-C) and the U.S. Centers for Disease Control and Prevention's (CDC) recommendations to encourage COVID-19 vaccination among children. Also cited are the MISC-C treatments like immunoglobulin therapy (IVIG) and steroids, and the possible role of the protein biomarker called zonulin in MIS-C.
- Published
- 2021
14. Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children.
- Author
-
Reiff DD and Cron RQ
- Subjects
- Humans, Child, SARS-CoV-2, Hospitalization, COVID-19 complications, COVID-19 epidemiology, Mucocutaneous Lymph Node Syndrome
- Abstract
Background : Multisystem inflammatory syndrome in children (MIS-C) is a severe, postinfectious manifestation of coronavirus disease 2019 (COVID-19) in the pediatric population. The disease is manifested by hyperinflammation and can result in cardiac dysfunction, coronary changes, and end-organ damage. Adequate timely treatment can prevent poor outcomes in the short term, but long-term data is lacking. Methods : A large single center MIS-C cohort was followed longitudinally after treatment with intravenous immunoglobulin (IVIG) ± glucocorticoids to determine the natural history of the disease and to describe improvement in laboratory markers and cardiac outcomes. Patient were stratified by disease severity and compared. Results : 137 patients were identified with demographics similar to previously described cohorts. Regardless of disease severity, when adequately treated, initial lab abnormalities rapidly improved by the 6-8 month follow-up period, with some resolved in as little as 1-2 weeks. Similarly, cardiac abnormalities improved quickly after treatment; all abnormalities resolved in this cohort by 1-2 months post-hospitalization. Conclusions : Although MIS-C is a serious sequela of COVID-19, when identified quickly and treated aggressively, laboratory abnormalities, coronary dilatation, and systolic dysfunction rapidly improve with minimal long-term morbidity or mortality.
- Published
- 2022
- Full Text
- View/download PDF
15. Hepatitis of unknown etiology in children: Current evidence and association.
- Author
-
Zhong R, Yi F, Xiang F, Qiu YF, Zhu L, Zou YH, Wang W, and Zhang Q
- Abstract
Two years after the coronavirus disease 2019 (COVID-19) pandemic, acute hepatitis of unknown etiology in children (AHUCD) began to be reported worldwide. The novel coronavirus and adenovirus were found in pathogen and antibody tests in AHUCD cases reported by the World Health Organization. Children are not exposed to the viruses that children are generally exposed to owing to COVID-19 infection preventive measures such as isolation and wearing masks; therefore, some researchers have speculated that this disease is related to reduced exposure to pathogens. Some scientists have also speculated that the disease is related to liver injury and adenoviral hepatitis, which are the sequelae of COVID-19. Some evidence also suggests a weak association between the disease and COVID-19 vaccination. Therefore, further research and investigation of the pathogenesis, preventive measures, and early treatment of hepatitis of unknown etiology are required. This study aimed to synthesize available evidence to further elucidate this disease in order to treat and prevent it effectively., Competing Interests: Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article., (©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
16. Microvasculature dysfunction as the common thread between atherosclerosis, Kawasaki disease, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated multi-system inflammatory syndrome in children
- Author
-
Erin C. Boyle and Axel Haverich
- Subjects
Pulmonary and Respiratory Medicine ,2019-20 coronavirus outbreak ,Eacts/166 ,Multi-system inflammatory syndrome in children ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Kawasaki's disease ,Mucocutaneous Lymph Node Syndrome ,medicine.disease_cause ,Microvasculature ,Medicine ,Humans ,Severe acute respiratory syndrome coronavirus 2 ,Child ,Coronavirus ,Kawasaki disease ,business.industry ,AcademicSubjects/MED00920 ,Eacts/170 ,Coronavirus disease 19 ,COVID-19 ,General Medicine ,medicine.disease ,Atherosclerosis ,Systemic Inflammatory Response Syndrome ,Microvascular Network ,Editorial ,Immunology ,Microvessels ,Surgery ,business ,Eacts/168 ,Cardiology and Cardiovascular Medicine ,Eacts/103 - Published
- 2020
- Full Text
- View/download PDF
17. Atrial fibrillation in a child with COVID-19 infection
- Author
-
Aura Daniella Santi, Paolo Aquino, and Molly V Dorfman
- Subjects
Male ,2019-20 coronavirus outbreak ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Adolescent ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,030204 cardiovascular system & hematology ,multi-system inflammatory syndrome in children ,03 medical and health sciences ,cardiac arrhythmia ,0302 clinical medicine ,Internal medicine ,Pandemic ,Atrial Fibrillation ,Medicine ,Humans ,Pediatrics, Perinatology, and Child Health ,business.industry ,Brief Report ,Cardiac arrhythmia ,COVID-19 ,Atrial fibrillation ,General Medicine ,medicine.disease ,New onset atrial fibrillation ,030228 respiratory system ,Pediatrics, Perinatology and Child Health ,Cardiology ,business ,Cardiology and Cardiovascular Medicine - Abstract
The SARS-CoV-2 (COVID-19) pandemic has challenged our initial predictions of its ramifications, both short and long term. Cardiovascular manifestations of COVID-19 in children remain a topic of investigation as literature is lacking. We describe new onset atrial fibrillation in a child with a history of COVID-19 infection. Understanding of cardiogenic effects of COVID-19 can help minimise the delay in diagnosis.
- Published
- 2020
- Full Text
- View/download PDF
18. Microvasculature dysfunction as the common thread between atherosclerosis, Kawasaki disease, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated multi-system inflammatory syndrome in children.
- Author
-
Boyle, Erin C and Haverich, Axel
- Subjects
- *
MUCOCUTANEOUS lymph node syndrome , *SARS-CoV-2 , *SYNDROMES , *ATHEROSCLEROSIS - Published
- 2020
- Full Text
- View/download PDF
19. Cardiac echocardiogram findings of severe acute respiratory syndrome coronavirus-2-associated multi-system inflammatory syndrome in children.
- Author
-
Harahsheh AS, Krishnan A, DeBiasi RL, Olivieri LJ, Spurney C, Donofrio MT, Cross RR, Sharron MP, Frank LH, Berul CI, Christopher A, Dham N, Srinivasalu H, Ronis T, Smith KL, Kline JN, Parikh K, Wessel D, Bost JE, Litt S, Austin A, Zhang J, and Sable CA
- Subjects
- Child, Child, Preschool, Humans, Retrospective Studies, SARS-CoV-2, Systemic Inflammatory Response Syndrome, COVID-19 complications, Cardiovascular Abnormalities, Coronary Artery Disease, Pericardial Effusion etiology
- Abstract
Background: A novel paediatric disease, multi-system inflammatory syndrome in children, has emerged during the 2019 coronavirus disease pandemic., Objectives: To describe the short-term evolution of cardiac complications and associated risk factors in patients with multi-system inflammatory syndrome in children., Methods: Retrospective single-centre study of confirmed multi-system inflammatory syndrome in children treated from 29 March, 2020 to 1 September, 2020. Cardiac complications during the acute phase were defined as decreased systolic function, coronary artery abnormalities, pericardial effusion, or mitral and/or tricuspid valve regurgitation. Patients with or without cardiac complications were compared with chi-square, Fisher's exact, and Wilcoxon rank sum., Results: Thirty-nine children with median (interquartile range) age 7.8 (3.6-12.7) years were included. Nineteen (49%) patients developed cardiac complications including systolic dysfunction (33%), valvular regurgitation (31%), coronary artery abnormalities (18%), and pericardial effusion (5%). At the time of the most recent follow-up, at a median (interquartile range) of 49 (26-61) days, cardiac complications resolved in 16/19 (84%) patients. Two patients had persistent mild systolic dysfunction and one patient had persistent coronary artery abnormality. Children with cardiac complications were more likely to have higher N-terminal B-type natriuretic peptide (p = 0.01), higher white blood cell count (p = 0.01), higher neutrophil count (p = 0.02), severe lymphopenia (p = 0.05), use of milrinone (p = 0.03), and intensive care requirement (p = 0.04)., Conclusion: Patients with multi-system inflammatory syndrome in children had a high rate of cardiac complications in the acute phase, with associated inflammatory markers. Although cardiac complications resolved in 84% of patients, further long-term studies are needed to assess if the cardiac abnormalities (transient or persistent) are associated with major cardiac events.
- Published
- 2022
- Full Text
- View/download PDF
20. Report of a Child With Febrile Status Epilepticus and Post-COVID Multi-System Inflammatory Syndrome.
- Author
-
Appleberry HC, Begezda A, Cheung H, Zaghab-Mathews S, and Mainali G
- Abstract
Multi-system Inflammatory Syndrome in Children (MIS-C) is a post infectious inflammatory syndrome following COVID infection. Previous case series have demonstrated that CNS involvement is less common and presents heterogeneously. The following case describes an infant with an initial presentation of refractory febrile status epilepticus. Genetic testing later showed multiple variants of uncertain significance. The patient met clinical criteria for MIS-C and had a markedly abnormal brain MRI with bilateral diffuse restricted diffusion (anterior > posterior). Clinically, the patient improved with pulse steroids and IVIg. This case highlights the importance of maintaining MIS-C in the differential as a trigger of Febrile Infection Related Epilepsy Syndrome (FIRES) with multi-organ involvement presenting 2-4 weeks after infectious symptoms and COVID exposure., Competing Interests: Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Gayatra Mainali—Member of Data Monitoring Committee for Molybdenum Cofactor Deficiency—Origin Biosciences., (© The Author(s) 2021.)
- Published
- 2021
- Full Text
- View/download PDF
21. Atrial fibrillation in a child with COVID-19 infection.
- Author
-
Santi AD, Aquino P, and Dorfman M
- Subjects
- Adolescent, Atrial Fibrillation therapy, COVID-19 therapy, Humans, Male, Atrial Fibrillation diagnosis, Atrial Fibrillation virology, COVID-19 complications, COVID-19 diagnosis
- Abstract
The SARS-CoV-2 (COVID-19) pandemic has challenged our initial predictions of its ramifications, both short and long term. Cardiovascular manifestations of COVID-19 in children remain a topic of investigation as literature is lacking. We describe new onset atrial fibrillation in a child with a history of COVID-19 infection. Understanding of cardiogenic effects of COVID-19 can help minimise the delay in diagnosis.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.